Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full length article — VialBase Research

Summary

Comprehensive review of BPC-157 (Body Protection Compound-157), a stable gastric pentadecapeptide originally isolated from human gastric juice. The paper covers its extensive cytoprotective and healing properties across multiple organ systems, including the GI tract, musculoskeletal system, and vascular system. BPC-157 has been investigated in clinical trials for inflammatory bowel disease.

Key Findings

• BPC-157 promotes healing of tendons, ligaments, bones, and muscle tissue in multiple animal models
• Demonstrated cytoprotective effects in the gastrointestinal tract, including against NSAID-induced damage
• Modulates the nitric oxide (NO) system, which appears central to its mechanism of action
• Promotes angiogenesis and wound healing through upregulation of growth factor expression (EGF, VEGF)
• Shows protective effects against various toxic agents and organ damage models
• Maintains stability in human gastric juice (unlike many other peptides)

Methodology

Narrative review synthesizing data from multiple preclinical studies conducted over two decades. Covers in-vitro, animal model, and early clinical trial data for BPC-157 in inflammatory bowel disease contexts.

Limitations

• Majority of evidence comes from animal models (primarily rat studies)
• Many studies originate from the same research group (Sikiric et al.)
• Limited independent replication of findings
• Human clinical trial data remains limited
• Mechanisms of action not fully elucidated

Relevance to Content

Foundational review paper for BPC-157 content. Establishes the breadth of preclinical evidence supporting healing and cytoprotective properties. Important for contextualizing the gap between extensive animal data and limited human data. Key reference for any article discussing BPC-157 mechanisms or therapeutic potential.

See Also

• Parent compound: BPC-157